Tags

Type your tag names separated by a space and hit enter

Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C in the treatment of primary pterygium.
Clin Exp Ophthalmol. 2006 Apr; 34(3):219-25.CE

Abstract

PURPOSE

To introduce a new technique of conjunctival reconstruction after primary pterygium excision, and to evaluate the efficacy of combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C application in preventing recurrence of primary pterygium.

METHODS

In a prospective, non-comparative case series, 43 eyes of 41 consecutive patients with primary pterygium were studied. In all patient eyes, after excision of pterygia, 0.02% mitomycin C was applied topically for 2 min over the exposed scleral surface and "symmetrical conjunctival flap transposition" was performed to reconstruct the conjunctival defect. The main outcome measures were pterygium recurrence or any complications related with surgery or mitomycin C.

RESULTS

The mean age of the patients was 47.5 +/- 12.4 years (range 30-70 years). Among the 38 patients who were not lost to follow up, three patient eyes (7.5%) had grade 1, 24 eyes (60.0%) had grade 2 and 13 eyes (32.5%) had grade 3 pterygium. The mean follow up was 12.2 +/- 5.7 months (range 7-28 months). No recurrence or sight-threatening complications were encountered in any patient eye throughout the follow-up period.

CONCLUSION

Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C application may be an effective surgical alternative in preventing recurrence of primary pterygium. Although the procedure seems to be free from severe complications, surgeons and patients should be well aware of the risk of late radiomimetic complications of mitomycin C. Comparative, randomized trials with more number of patients and longer follow up are required to further establish the safety and efficacy of this treatment strategy.

Authors+Show Affiliations

Department of Ophthalmology, Ankara University School of Medicine, Cankaya 06680, Ankara, Turkey. omuru@yahoo.comNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16671901

Citation

Uçakhan, Omür O., and Ayfer Kanpolat. "Combined "symmetrical Conjunctival Flap Transposition" and Intraoperative Low-dose Mitomycin C in the Treatment of Primary Pterygium." Clinical & Experimental Ophthalmology, vol. 34, no. 3, 2006, pp. 219-25.
Uçakhan OO, Kanpolat A. Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C in the treatment of primary pterygium. Clin Exp Ophthalmol. 2006;34(3):219-25.
Uçakhan, O. O., & Kanpolat, A. (2006). Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C in the treatment of primary pterygium. Clinical & Experimental Ophthalmology, 34(3), 219-25.
Uçakhan OO, Kanpolat A. Combined "symmetrical Conjunctival Flap Transposition" and Intraoperative Low-dose Mitomycin C in the Treatment of Primary Pterygium. Clin Exp Ophthalmol. 2006;34(3):219-25. PubMed PMID: 16671901.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C in the treatment of primary pterygium. AU - Uçakhan,Omür O, AU - Kanpolat,Ayfer, PY - 2006/5/5/pubmed PY - 2006/6/20/medline PY - 2006/5/5/entrez SP - 219 EP - 25 JF - Clinical & experimental ophthalmology JO - Clin Exp Ophthalmol VL - 34 IS - 3 N2 - PURPOSE: To introduce a new technique of conjunctival reconstruction after primary pterygium excision, and to evaluate the efficacy of combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C application in preventing recurrence of primary pterygium. METHODS: In a prospective, non-comparative case series, 43 eyes of 41 consecutive patients with primary pterygium were studied. In all patient eyes, after excision of pterygia, 0.02% mitomycin C was applied topically for 2 min over the exposed scleral surface and "symmetrical conjunctival flap transposition" was performed to reconstruct the conjunctival defect. The main outcome measures were pterygium recurrence or any complications related with surgery or mitomycin C. RESULTS: The mean age of the patients was 47.5 +/- 12.4 years (range 30-70 years). Among the 38 patients who were not lost to follow up, three patient eyes (7.5%) had grade 1, 24 eyes (60.0%) had grade 2 and 13 eyes (32.5%) had grade 3 pterygium. The mean follow up was 12.2 +/- 5.7 months (range 7-28 months). No recurrence or sight-threatening complications were encountered in any patient eye throughout the follow-up period. CONCLUSION: Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C application may be an effective surgical alternative in preventing recurrence of primary pterygium. Although the procedure seems to be free from severe complications, surgeons and patients should be well aware of the risk of late radiomimetic complications of mitomycin C. Comparative, randomized trials with more number of patients and longer follow up are required to further establish the safety and efficacy of this treatment strategy. SN - 1442-6404 UR - https://www.unboundmedicine.com/medline/citation/16671901/Combined_"symmetrical_conjunctival_flap_transposition"_and_intraoperative_low_dose_mitomycin_C_in_the_treatment_of_primary_pterygium_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=16671901.ui DB - PRIME DP - Unbound Medicine ER -